A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Inclusion Criteria

- Have T2DM at Screening visit

- Be on metformin monotherapy ≥1500 mg/day alone or in combination with an sulfonylurea
agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational
site) for ≥8 weeks

- Is a male or a female not of reproductive potential (defined as one who is
postmenopausal or has had a hysterectomy and/or bilateral oophorectomy, or had
bilateral tubal ligation or occlusion at least 6 weeks prior to Screening visit). If
participant is a female of reproductive potential, must agree to remain abstinent
from heterosexual activity or agrees to use (or have her partner use) acceptable
contraception to prevent pregnancy while receiving blinded study drug and for 14 days
after the last dose of blinded study drug

Exclusion Criteria:

- Has a history of type 1 diabetes mellitus or a history of ketoacidosis

- Has a history of secondary causes of diabetes

- Has a known hypersensitivity or intolerance to any dipeptidyl peptidase IV (DPP-4)
inhibitor or sodium-glucose cotransporter 2 (SGLT2) inhibitor

- Has been treated with any anti-hyperglycemic agents (AHA) other than metformin and
for participants on dual combination therapy, a sulfonylurea within 12 weeks of
screening

- Intends to initiate weight loss medication during the study period

- Has undergone bariatric surgery within 12 months of Screening visit

- Has started a weight loss medication or a medication associated with weight changes
within the prior 12 weeks.

- Has a history of myocardial infarction, unstable angina, arterial revascularization,
stroke, transient ischemic attack, heart failure within 3 months of Screening visit

- Has a history of malignancy ≤5 years prior to study, except for adequately treated
basal cell or squamous cell skin cancer or in situ cervical cancer

- Has human immunodeficiency virus (HIV)

- Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells,
or clinically important hematological disorder (such as aplastic anemia,
myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

- Has a medical history of active liver disease (other than non-alcoholic hepatic
steatosis), including chronic hepatitis B or C, primary biliary cirrhosis, or
symptomatic gallbladder disease

- Is currently being treated for hyperthyroidism or is on thyroid replacement therapy
and has not been on a stable dose for at least 6 weeks prior to Screening visit

- Is on or likely to require treatment for ≥14 consecutive days or repeated courses of
corticosteroids

- Is on or likely to require treatment for ≥7 consecutive days with non-steroidal
anti-inflammatory drugs

- Is pregnant or breast-feeding, or is planning to conceive during the study, including
14 days following the last dose of blinded study drug

- Is planning to undergo hormonal therapy in preparation to donate eggs during the
study, including 14 days following the last dose of blinded study drug

- Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week or
engages in binge drinking

- Has donated blood or blood products within 6 weeks of Screening visit or who plans to
donate blood or blood products at any time during the study